AVGR vs. DRUG, THAR, LIXT, EVOK, UTRS, KZIA, NVTA, XCUR, BIOL, and FRTX
Should you be buying Avinger stock or one of its competitors? The main competitors of Avinger include Bright Minds Biosciences (DRUG), Tharimmune (THAR), Lixte Biotechnology (LIXT), Evoke Pharma (EVOK), Minerva Surgical (UTRS), Kazia Therapeutics (KZIA), Invitae (NVTA), Exicure (XCUR), BIOLASE (BIOL), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "medical" sector.
Avinger (NASDAQ:AVGR) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and community ranking.
18.3% of Avinger shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 4.3% of Avinger shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Bright Minds Biosciences has lower revenue, but higher earnings than Avinger. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.
Avinger currently has a consensus target price of $5.00, suggesting a potential upside of 70.07%. Given Avinger's higher probable upside, analysts clearly believe Avinger is more favorable than Bright Minds Biosciences.
Avinger has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
In the previous week, Avinger had 11 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 12 mentions for Avinger and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.90 beat Avinger's score of 0.57 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.
Bright Minds Biosciences has a net margin of 0.00% compared to Avinger's net margin of -239.41%. Bright Minds Biosciences' return on equity of -91.83% beat Avinger's return on equity.
Avinger received 393 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users.
Summary
Bright Minds Biosciences beats Avinger on 9 of the 15 factors compared between the two stocks.
Get Avinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools